M&A

Celgene wins approval for drug key to Bristol buyout
Celgene wins approval for drug key to Bristol buyout
Biopharma Dive
Celgene
FDA
Inrebic
myelofibrosis
M&A
Bristol-Myers Squibb
Flag link:
This Joint Is Jumping: PE Firms Knee-Deep In Orthopedic Space
This Joint Is Jumping: PE Firms Knee-Deep In Orthopedic Space
Forbes
devices
Orthopedics
M&A
private equity
Flag link:
Ultragenyx Inks a Partner-to-Buy Deal with GeneTx to Develop Treatment for Rare Genetic Syndrome
Ultragenyx Inks a Partner-to-Buy Deal with GeneTx to Develop Treatment for Rare Genetic Syndrome
BioSpace
Ultragenyx
GeneTx Biotherapeutics
Angelman Syndrome
M&A
Flag link:
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Fierce Pharma
Allergan
executive pay
Pharma CEOs
Brent Saunders
AbbVie
M&A
Flag link:
As investors fret about Xyrem durability, Jazz spends $52M+ upfront to swallow neuro-focused biotech
As investors fret about Xyrem durability, Jazz spends $52M+ upfront to swallow neuro-focused biotech
Endpoints
Jazz Pharma
Xyrem
Cavion
M&A
Flag link:
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Fierce Pharma
AbbVie
Allergan
M&A
Flag link:
Will This Be a Busy Summer for M&A in Medtech?
Will This Be a Busy Summer for M&A in Medtech?
Medical Devices and Diagnostics Industry
M&A
devices
AtriCure
SentreHEART
Flag link:
BridgeBio looks to fully own its CV subsidiary Eidos
BridgeBio looks to fully own its CV subsidiary Eidos
BioCentury
BridgeBio
M&A
Eidos Therapeutics
Flag link:
Hikma Pharmaceuticals acquires manufacturing platform, two pipeline products from Insys Therapeutics
Hikma Pharmaceuticals acquires manufacturing platform, two pipeline products from Insys Therapeutics
Stockmarket Wire
Hikma
INSYS Therapeutics
M&A
drug manufacturing
Flag link:
Lilly shuffles executives overseeing oncology and M&A
Lilly shuffles executives overseeing oncology and M&A
Biopharma Dive
Eli Lilly
oncology
M&A
Flag link:
Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work
Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work
Xconomy
Bayer
Versant Ventures
cell therapy
M&A
BlueRock Therapeutics
Flag link:
Bayer, Elanco could lock up animal health merger next week: report
Bayer, Elanco could lock up animal health merger next week: report
Fierce Pharma
Bayer
Elanco
M&A
animal health
Flag link:
More M&A Activity Expected Around AAV-Based Gene Therapies, Analyst Says
More M&A Activity Expected Around AAV-Based Gene Therapies, Analyst Says
BioSpace
gene therapy
M&A
Audentes Therapeutics
Regenxbio
Passage Bio
Flag link:
Celgene Continues Growing While Waiting for its Acquisition to Close
Celgene Continues Growing While Waiting for its Acquisition to Close
Motley Fool
Celgene
earnings
M&A
Bristol-Myers Squibb
Flag link:
Allergan says it will shed two drugs as AbbVie takeover looms
Allergan says it will shed two drugs as AbbVie takeover looms
Pharmaforum
Allergan
brazikumab
Zenprep
AbbVie
M&A
Flag link:
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
Fierce Pharma
Allergan
AbbVie
Botox
M&A
Flag link:
Mylan-Upjohn Merger Leaves Analysts Skeptical
Mylan-Upjohn Merger Leaves Analysts Skeptical
Xtalks
analysts
M&A
Mylan
Pfizer
Upjohn
Flag link:
After Mylan Gets Acquired, Could Teva Be Next?
After Mylan Gets Acquired, Could Teva Be Next?
Yahoo/Guru Focus
Pfizer
Upjohn
Mylan
Teva Pharmaceutical
M&A
Flag link:
Digital health M&A bounces back in Q2
Digital health M&A bounces back in Q2
Pharmaforum
digital health
M&A
Flag link:
Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Fierce Pharma
Korea
Shire
Takeda
employees
M&A
Flag link:

Pages